DVT as a feature of #VITT: unusual in the UK / Europe yet common in Australia - could cases have been missed?
NB this is a loose theory, not an assertion
Here are some observations
On 20 May ATAGI reported a breakdown of types of clot seen in 🇦🇺 VITT cases
Of 21 confirmed + 3 probable cases, DVT was present in 12 (50%)
Even excl. probables + assuming all 3 included DVT, that would mean DVT present in minimum 9 / 21 = 43% VITT cases tga.gov.au/periodic/covid…
In Europe only 3 / 45 (7%) cases across 4 published papers (Schultz, Greinacher, Scully, Tiede) + 1 unpublished study (Scavone) include DVT according to a paper by M Cattaneo
This is strikingly different from the Australian data - what could explain it?
1/ Risk of selection bias in the case series which makes the 45 European cases unrepresentative of VITT cases in Europe generally?
Seems not to be the case, the various papers suggest all patients who met the criteria for VITT were included, none mention excluding cases
Cattaneo (a haematology professor) also specifically comments on the low occurrence of DVT in VITT cases, particularly notable in its absence in cases of PE, suggesting most clots in the lungs in VITT form de novo in the pulmonary vessels rather than starting life as DVTs
2/ Could Australia be using a broader definition of VITT, therefore counting cases which are not "real" VITT?
No, Australia only counts as "confirmed" VITT cases which include thrombosis, thrombocytopenia, high D-dimer and test positive for anti-PF4
3/ Could the difference be down to chance?
DVT was present in at least 43% of 🇦🇺VITT but only 7% of 🇬🇧🇪🇺🇳🇴VITT
The sample sizes are small and np = 3 for the European data meaning the normal approximation cannot be used
However...
... *even if* Europe had seen more DVTs (say, 5 instead of 3 to permit the normal approximation to the binomial) that would mean comparing 43% and 11% which gives a p value of 0.004
This suggests the difference is not due to chance alone (albeit sample sizes are small)
So what could be going on?
One difference between the 🇦🇺 cases and the European cases is age. Australia limited #AZ to over 50s in early April, meaning most (75%) of its #VITT cases have been in over 50s
In contrast most of the 45 European cases (over 70%) were in under 50s
Could this mean DVT is more frequent in VITT in older patients and that 🇦🇺 is detecting more VITT cases than in Europe in older patients?
ATAGI suggests that 🇦🇺 is indeed identifying more #VITT cases than in other countries
This is also supported by the published incidence rates per 100k of 2.6 in under 50s and 1.6 in over 50s in Australia, vs 2 (under 40) and 1 (over 40) in the UK
It is difficult to draw conclusions using relatively small samples, however...
It seems plausible #VITT cases have been missed in UK and Europe
Available data suggests DVT within VITT is more common in over 50s, with the low reported frequency of DVT in VITT outside Australia potentially pointing to under-reporting of VITT specifically in older patients
• • •
Missing some Tweet in this thread? You can try to
force a refresh
As an add-on to my thread explaining why regulators are unlikely to detect an increase in the risk of blood clots generally due to the #AstraZenecaVaccine (annotated 100% with #JurassicPark GIFs!) I present:
Hang on a minute, *does* AZ increase overall clot risk??
[thread]
The previous thread outlined how the analysis done by #EMA and #MHRA to detect an increase in the incidence of #BloodClots after AZ was crap because they forgot they were dealing with vaccine reporting (reports filed *if* someone suspects vax link) and…
*not* a clinical trial where participants are monitored and all health issues are reported
So they ended up comparing a huge baseline rate to the tiny number of clots that actually got reported to them and now they think the AZ vaccine reduces the risk of blood clots by 98%
If AstraZeneca increased the risk of common blood clots, as well as the rare and dangerous ones, would we even know about it?
[thread]
The focus of the blood clot risk of the AstraZeneca vaccine has been on the clots in unusual (and dangerous) sites such as the brain and abdomen that have been found alongside low platelets (thrombocytopenia)
Thanks to Norway and Denmark, this new syndrome was rapidly identified and reported as a risk, even if certain parties were initially in denial (looking at you MHRA)
Oxford’s Dodgy Dossier (Part 1): How Oxford University researchers twisted facts and manipulated statistics to make the Oxford vaccine look better and mRNA vaccines look worse
Last week a group of Oxford scientists released a pre-print comparing the incidence of dangerous (1/x)
blood clots in the two weeks following 1) a Covid diagnosis 2) vaccination with the Oxford vaccine 3) vaccination with an mRNA vaccine
While the main headline grabber of the report was the claim that Covid infection carries a higher risk of blood (2/x)
clots than the Oxford vaccine, the paper also claimed the incidence of unusual, dangerous blood clots after mRNA vaccines was much, much higher than after the Oxford vaccine
To be specific, the paper claimed that 4 out of every million people vaccinated with an mRNA (3/x)